Undifferentiated Connective-Tissue Disease Medication: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Nonsteroidal Anti-Inflammatory Drug (NSAID), Cox-2 Selective, Antimalarials, Corticosteroids, Immunosuppressant agents, Calcium channel blockers, Pulmonary, Tyrosine Kinase Inhibitors
https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUuc3RhZ2luZy5tZWRzY2FwZS5jb20vYXJ0aWNsZS8zMzQ0ODItbWVkaWNhdGlvbg==
Undifferentiated Connective-Tissue Disease Medication
Mosca et al (2008) found that 93% of patients with UCTD were initially treated with corticosteroids and/or antimalarials, and 2% were started on immunosuppressive medications. After 10 years of follow-up, 16% of patients were no longer receiving therapy, 36% were being treated with hydroxychloroquine plus corticosteroids, 10% were taking corticosteroids alone, and no patients were receiving cytotoxic immunosuppressive therapy. [22]
Bodolay et al (2003) prescribed low-dose corticosteroids only when NSAIDs were deemed ineffective. [19] Common indications for systemic corticosteroids included recurrent serositis, skin vasculitis, and synovitis. Antimalarials were administered for photosensitivity and severe rash. The authors concluded that aggressive immunosuppressive therapy for "true" UCTD is neither necessary nor justified.